Cost-effectiveness and price threshold analysis of daraxonrasib versus chemotherapy for previously treated metastatic pancreatic ductal adenocarcinoma in China
Kosten-Effektivitäts- und Preisschwellenanalyse von Daraxonrasib gegenüber Chemotherapie bei vorbehandeltem metastasiertem Pankreasduktalem Adenokarzinom in China
Frontiers in Pharmacology · 12.11.2026 · 17
DOI: 10.3389/fphar.2026.1930284 ↗Auf einen Blick
Daraxonrasib brachte bei vorbehandeltem mPDAC 0,30 zusätzliche QALYs, war aber gegenüber Chemotherapie in China nicht kosteneffektiv.
Fragestellung
Ist Daraxonrasib gegenüber Chemotherapie bei vorbehandeltem metastasiertem Pankreasduktalem Adenokarzinom in China kosteneffektiv?
Methode
Drei-Zustands-Partitioned-Survival-Modell aus Sicht des chinesischen Gesundheitssystems; Daten aus der RASolute-302-RCT; 10-Jahres-Horizont, 4,5 % Diskontierung.
Ergebnisse
0,30 zusätzliche QALYs (0,98 vs. 0,68) bei Mehrkosten von US$38.125,89 (US$44.844,71 vs. US$6.718,82). ICER: US$127.020,77 pro QALY, über der Zahlungsbereitschaftsschwelle.
Schlussfolgerung der Autor:innen
Aus Sicht des chinesischen Gesundheitssystems bietet Daraxonrasib zwar zusätzliche klinische Vorteile, ist bei dem angenommenen Preis von US$5.000 pro Behandlungszyklus aber wahrscheinlich nicht kosteneffektiv.
Kernaussagen
- 0,30 zusätzliche QALYs unter Daraxonrasib
- ICER: US$127.020,77 pro QALY
- Preisreduktionen wären nötig, um die Schwelle zu erreichen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.11.2026. Verfasst von Ruijia Chen und 9 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a highly lethal malignancy with limited treatment options after first-line progression. Daraxonrasib (RMC-6236), a RAS(ON) inhibitor, has demonstrated clinical benefit in previously treated mPDAC patients in the RASolute 302 trial. However, its economic value in China remains uncertain. This study evaluated the cost-effectiveness of Daraxonrasib versus Chemotherapy in previously treated mPDAC.
Methods
A three-state partitioned survival model was developed to evaluate costs and health outcomes from the Chinese healthcare system perspective. Clinical inputs were derived from reconstructed individual patient data from the RASolute 302 randomized clinical trial, with long-term survival extrapolated using parametric survival models. Costs were estimated using China-specific healthcare resource utilization and medical service prices. Outcomes included costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). A 10-year time horizon with an annual discount rate of 4.5% was applied. Deterministic sensitivity analyses, probabilistic sensitivity analyses, and price scenario analyses were performed.
Results
Compared with chemotherapy, the model estimated that daraxonrasib generated an additional 0.30 QALYs (0.98 vs. 0.68 QALYs) at an increased cost of US$38,125.89 (US$44,844.71 vs. US$6,718.82), resulting in an ICER of US$127,020.77 per QALY gained, which exceeded the Chinese willingness-to-pay threshold. Sensitivity analyses identified the acquisition cost of daraxonrasib, rather than chemotherapy drug costs, as the most influential determinant of cost-effectiveness. Price threshold analyses suggested that substantial price reductions would be required for daraxonrasib to approach the willingness-to-pay threshold.
Conclusion
From the perspective of the Chinese healthcare system, daraxonrasib provides additional clinical benefits for previously treated patients with mPDAC but is unlikely to be cost-effective compared with chemotherapy at the assumed price of US$5,000 per treatment cycle. Pricing strategies and reimbursement negotiations will be critical determinants of its potential economic value in China.
Zitieren
APA
Chen, R., Fu, M., Lin, H., Jiang, Q., Li, C., Xu, L., Wu, R., Zhang, K., Chen, Y., & Wu, L. (2026). Cost-effectiveness and price threshold analysis of daraxonrasib versus chemotherapy for previously treated metastatic pancreatic ductal adenocarcinoma in China. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1930284
Vancouver
Chen R, Fu M, Lin H, Jiang Q, Li C, Xu L, et al. Cost-effectiveness and price threshold analysis of daraxonrasib versus chemotherapy for previously treated metastatic pancreatic ductal adenocarcinoma in China. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1930284
BibTeX
@article{Chen2026,
author = {Chen, Ruijia and Fu, Minghai and Lin, Hui and Jiang, Qingna and Li, Chaoqi and Xu, Longlong and Wu, Ruofei and Zhang, Kun and Chen, Youting and Wu, Lixian},
title = {Cost-effectiveness and price threshold analysis of daraxonrasib versus chemotherapy for previously treated metastatic pancreatic ductal adenocarcinoma in China},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1930284}
}
EUVIMED